Search research articles
Contact Us
Filters
Showing results (51-60 of 98) with videos related to
Page
of 10
Sort By:
Clinical Therapeutics
|
February 20, 2022
Population Pharmacokinetic and Exposure-Response Model Simulations: Predicted Exposure and Efficacy for Maintenance Doses of Intravenous Golimumab Every 6 or 8 Weeks in Patients With Moderately to Severely Active Rheumatoid Arthritis
Jong Bong Lee, Aaron Broadwell, Yijun Fan, et al.
Arthritis Research & Therapy
|
March 22, 2022
Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis
M Elaine Husni, Atul Deodhar, Sergio Schwartzman, et al.
Paediatric Drugs
|
October 29, 2025
Extrapolating Guselkumab Efficacy to Juvenile Psoriatic Arthritis from Adult Psoriatic Arthritis and Adult and Pediatric Psoriasis Data
Herta Crauwels, Sarah Ringold, Samantha Howard, et al.
Arthritis Research & Therapy
|
March 8, 2020
Inhibition of radiographic progression across levels of composite index-defined disease activity in patients with active psoriatic arthritis treated with intravenous golimumab: results from a phase-3, double-blind, placebo-controlled trial
Philip Mease, M Elaine Husni, Shelly Kafka, et al.
Clinical Rheumatology
|
May 2, 2021
Healthcare utilization and costs among patients with psoriasis and psoriatic arthritis in the USA-a retrospective study of claims data from 2009 to 2020
J F Merola, N Dennis, S D Chakravarty, et al.
RMD Open
|
March 27, 2020
Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials
Philip S Helliwell, Dafna D Gladman, Soumya D Chakravarty, et al.
Rheumatology and Therapy
|
October 11, 2023
Efficacy of Guselkumab on Axial-Related Symptoms Through up to 2 Years in Adults with Active Psoriatic Arthritis in the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Study
Philip J Mease, Dafna D Gladman, Denis Poddubnyy, et al.
The Journal of Rheumatology
|
July 15, 2022
Effect of Fatigue on Health-Related Quality of Life and Work Productivity in Psoriatic Arthritis: Findings From a Real-World Survey
Laure Gossec, Jessica A Walsh, Kaleb Michaud, et al.
Drugs - Real World Outcomes
|
October 15, 2022
Clinical Characteristics of Registry Participants with Psoriatic Arthritis Initiating Guselkumab: An Analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Philip J Mease, Alexis Ogdie, Soumya D Chakravarty, et al.
BMC Rheumatology
|
February 3, 2024
Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study
Laura C Coates, Proton Rahman, Philip J Mease, et al.
Page
of 10
Search research articles
Search
Showing results (51-60 of 98) with videos related to
Sort By:
Page
of 10
Clinical Therapeutics
|
February 20, 2022
Population Pharmacokinetic and Exposure-Response Model Simulations: Predicted Exposure and Efficacy for Maintenance Doses of Intravenous Golimumab Every 6 or 8 Weeks in Patients With Moderately to Severely Active Rheumatoid Arthritis
Jong Bong Lee, Aaron Broadwell, Yijun Fan, et al.
Arthritis Research & Therapy
|
March 22, 2022
Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis
M Elaine Husni, Atul Deodhar, Sergio Schwartzman, et al.
Paediatric Drugs
|
October 29, 2025
Extrapolating Guselkumab Efficacy to Juvenile Psoriatic Arthritis from Adult Psoriatic Arthritis and Adult and Pediatric Psoriasis Data
Herta Crauwels, Sarah Ringold, Samantha Howard, et al.
Arthritis Research & Therapy
|
March 8, 2020
Inhibition of radiographic progression across levels of composite index-defined disease activity in patients with active psoriatic arthritis treated with intravenous golimumab: results from a phase-3, double-blind, placebo-controlled trial
Philip Mease, M Elaine Husni, Shelly Kafka, et al.
Clinical Rheumatology
|
May 2, 2021
Healthcare utilization and costs among patients with psoriasis and psoriatic arthritis in the USA-a retrospective study of claims data from 2009 to 2020
J F Merola, N Dennis, S D Chakravarty, et al.
RMD Open
|
March 27, 2020
Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials
Philip S Helliwell, Dafna D Gladman, Soumya D Chakravarty, et al.
Rheumatology and Therapy
|
October 11, 2023
Efficacy of Guselkumab on Axial-Related Symptoms Through up to 2 Years in Adults with Active Psoriatic Arthritis in the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Study
Philip J Mease, Dafna D Gladman, Denis Poddubnyy, et al.
The Journal of Rheumatology
|
July 15, 2022
Effect of Fatigue on Health-Related Quality of Life and Work Productivity in Psoriatic Arthritis: Findings From a Real-World Survey
Laure Gossec, Jessica A Walsh, Kaleb Michaud, et al.
Drugs - Real World Outcomes
|
October 15, 2022
Clinical Characteristics of Registry Participants with Psoriatic Arthritis Initiating Guselkumab: An Analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Philip J Mease, Alexis Ogdie, Soumya D Chakravarty, et al.
BMC Rheumatology
|
February 3, 2024
Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study
Laura C Coates, Proton Rahman, Philip J Mease, et al.
Page
of 10